AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03567499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
Study NCT01077024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking-cessation treatment
Description: Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
Study NCT03984760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Take the capsules with meals or immediately after meals.
Study NCT03984760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Take the tablets with meals.
Study NCT02292134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: earplug and sleep mask
Description: Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
Study NCT04761380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: balloon-based tongue pressure measurement device
Description: The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
Study NCT00401973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 milligrams (mg), oral, daily for 22 weeks.
Study NCT00942240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: administered orally once a day for 14 days
Study NCT00942240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo tablet
Description: administered orally once a day for 14 days
Study NCT03750773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 600mg
Description: Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
Study NCT03750773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
Study NCT02874846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02%
Description: Once daily in both eyes (OU) in the evening (PM) for 7 days
Study NCT03714373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
Study NCT03714373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
Study NCT03714373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DCCR
Description: Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
Study NCT00866580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate influenza vaccine 1562902A
Description: Intramuscular dose on Day 0 and Day 21
Study NCT00866580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
Study NCT02874846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution Vehicle
Description: Once daily in both eyes (OU) in the evening (PM) for 7 days
Study NCT03059836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n3 PUFA-enriched fish oil
Description: 3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
Study NCT03059836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Organic Sunflower Oil 5000mg per day
Study NCT00401973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine
Description: Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
Study NCT00401973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
Study NCT00401973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Zonisamide, 100-400mg, oral, daily.
Study NCT00401973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness education
Description: weight management
Study NCT00474630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/bupropion SR 360 mg/ day
Study NCT00474630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00474630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study NCT00474630 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study NCT03515538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 for injection
Study NCT03515538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
Study NCT03515538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin for injection
Description: Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
Study NCT03515538 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
Study NCT03515538 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
Study NCT01950936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of Antibiotcs
Description: Discontinuation of Antibiotcs against lower respiratory tract infections
Study NCT00866580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
Study NCT00624351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
Study NCT00624351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.
Study NCT00624351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate-buffered Saline (PBS) infusion.
Study NCT04595669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised advise
Description: personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
Study NCT02349672 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: Blood will be collected to test for concentrations of UCH-L1 and GFAP.
Study NCT03318874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blephasteam
Description: Steam delivery goggles, once daily
Study NCT03318874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THERA°PEARL Eye Mask
Description: Heat delivery device, delivering heat to the eyelids, once daily
Study NCT03318874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylo-comod
Description: Tear substitute containing hyaluronic acid, four times daily
Study NCT03232762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined Grains
Description: In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
Study NCT03232762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole Grains
Description: In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
Study NCT01189656 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HBV DNA Vaccine
Description: HBV DNA Vaccine, 1mg/ml/syringe, formulation
Study NCT01189656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV DNA Vaccine
Description: HBV DNA Vaccine, 1mg/ml/syringe, formulation
Study NCT03318874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-comod
Description: Tear substitute containing hyaluronic acid, four times daily
Study NCT02585180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
Study NCT01728116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
Study NCT01728116 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Endoscopic evaluation but no device placement
Study NCT02235870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obalon Intragastric Balloons
Description: Intragastric Balloon System to aid in portion control.
Study NCT02235870 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham Intragastric Balloon
Study NCT02235870 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition and Lifestyle Program
Description: Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
Study NCT03666143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule
Study NCT03666143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT00552539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'educational video'
Description: 'educational video'
Study NCT02235870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Lifestyle Program
Description: Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
Study NCT01318811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilute unfractionated heparin
Description: Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
Study NCT01318811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard concentration unfractionated heparin
Description: Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
Study NCT03259165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrates
Description: For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If \< 15, stop algorithm.
Study NCT00576693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracranial angioplasty and stenting
Description: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
Study NCT00576693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive medical management
Description: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
Study NCT03242759 — intervention group
Intervention type: DRUG
Intervention: nintedanib
Description: Drug
Study NCT03242759 — intervention group
Intervention type: DRUG
Intervention: pirfenidone
Description: Drug
Study NCT03259165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loop Diuretics
Description: For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If \< 15, stop algorithm.
Study NCT05805540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold-water immersion
Description: Subjects were immersed, in a sitting position where legs were always covered, in cold water at 11ºC in periods of 2 minutes submerged and 2 minutes out of the water at room temperature (25ºC), repeating this process 5 times
Study NCT05805540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protein-carbohydrates supplementation
Description: Subjects consumed a mixed carbohydrate and protein beverage, composed of 0.3gr/kg of maltodextrin and 0.2gr/kg of neutral whey protein in 0.5 litres of water. Subject sat for 25 minutes until all recovery methods were completed.
Study NCT02412358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush
Study NCT04003363 — intervention group
Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study NCT02600247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Study NCT02600247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Description: Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Study NCT04366271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal cells
Description: 1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
Study NCT04366271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Best treatment option for COVID-19 according to investigator criteria
Study NCT02600247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Description: Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone
Study NCT00681486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Study NCT00681486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Study NCT04162899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
Study NCT04239560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boron-based Gel (Fibore)
Description: During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
Study NCT04239560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
Study NCT03280550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
Study NCT03280550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study NCT00976573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00976573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study NCT00976573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02585180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.